Human periodontal ligament stem cell seeding on calcium phosphate cement scaffold delivering metformin for bone tissue engineering

(1) develop a CPC-metformin scaffold with hPDLSC seeding for bone tissue engineering; and (2) investigate the effects of CPC-metformin scaffold on hPDLSC proliferation, osteogenic differentiation and bone matrix mineralization for the first time. hPDLSCs were harvested from extracted teeth. CPC scaf...

Full description

Saved in:
Bibliographic Details
Published in:Journal of dentistry 2019-12, Vol.91, p.103220-103220, Article 103220
Main Authors: Zhao, Zeqing, Liu, Jin, Schneider, Abraham, Gao, Xianling, Ren, Ke, Weir, Michael D., Zhang, Ning, Zhang, Ke, Zhang, Li, Bai, Yuxing, Xu, Hockin H.K.
Format: Article
Language:English
Subjects:
Antidiabetics
Biomedical materials
Bone growth
Bone healing
Bone matrix
Bone tissue engineering
Bones
Calcium phosphate cement
Calcium phosphates
Carbon dioxide
Cement
Cholecystokinin
Cytology
Defects
Dental materials
Dentistry
Differentiation (biology)
FDA approval
Human teeth
Kinases
Ligaments
Metformin
Mineralization
Morphology
Orthodontics
Orthopedics
Osteogenic differentiation
Periodontal ligament
Periodontal ligament stem cells
Regeneration
Scaffolds
Stem cells
Studies
Synthesis
Teeth
Tissue engineering
Viability
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:(1) develop a CPC-metformin scaffold with hPDLSC seeding for bone tissue engineering; and (2) investigate the effects of CPC-metformin scaffold on hPDLSC proliferation, osteogenic differentiation and bone matrix mineralization for the first time. hPDLSCs were harvested from extracted teeth. CPC scaffolds (with or without metformin) were prepared. Three groups were tested: (1) control group (growth medium); (2) osteogenic group (osteogenic medium); (3) metformin + osteogenic group (CPC-metformin scaffold, cultured in osteogenic medium). hPDLSC viability, osteogenic differentiation and mineralization were measured. SEM was used to examine cell morphology. After culturing for 14 days, all three groups demonstrated excellent hPDLSC attachment and viability, as shown in live-dead staining, CCK-8 assay, and SEM examinations. The osteogenic group had 3–8 folds, 5 folds and 6 folds of increases in osteogenic gene expressions, ALP activity and mineral synthesis, compared to control group. Furthermore, the metformin + osteogenic group had 3-fold to 4-fold increases over those of the osteogenic group in osteogenic gene expressions, ALP activity and mineral synthesis. hPDLSCs were demonstrated to be a potent cell source for bone engineering. The novel CPC-metformin-hPDLSC construct is highly promising to enhance bone repair and regeneration efficacy in dental, craniofacial and orthopedic applications.
ISSN:0300-5712
1879-176X
DOI:10.1016/j.jdent.2019.103220